From Medscape Diabetes & Endocrinology

Coverage from the

European Association for the Study of Diabetes (EASD) 2017 Annual Meeting

September 11 - 15, 2017; Lisbon, Portugal

September 11 - 15, 2017 Lisbon, Portugal

EASD New Dawn in Diabetes: Apps Can Improve Compliance, With Caveats There's no escaping technology any more when it comes to managing diabetes, from simple apps that help with carb counting to more complex software linking continuous glucose monitors to smartphones.
Medscape Medical News, October 6, 2017
EASD Genetic Research Informs on Timing of Type 1 Diabetes Development Two studies point to possible improvements in predicting which autoantibody-positive people might progress to type 1 diabetes and in distinguishing between types in adult-onset diabetes.
Medscape Medical News, October 3, 2017
EASD Twice-Daily Aspirin Better to Prevent CVD in Diabetes? An early study suggests that more frequent aspirin dosing might up antiplatelet protection in patients with type 2 diabetes, but these lab findings require verification in clinical studies.
Medscape Medical News, October 2, 2017

Conference News

EASD New Dawn in Diabetes: Apps Can Improve Compliance, With Caveats
Medscape Medical News, October 6, 2017
EASD Genetic Research Informs on Timing of Type 1 Diabetes Development
Medscape Medical News, October 3, 2017
EASD Twice-Daily Aspirin Better to Prevent CVD in Diabetes?
Medscape Medical News, October 2, 2017
EASD Eyedrops for Diabetic Retinopathy Possible in the Future?
Medscape Medical News, September 28, 2017
EASD Tool Predicts Added Disease-Free Life With Drug Changes in Diabetes
Medscape Medical News, September 27, 2017
EASD Another SGLT2 Inhibitor, Ertugliflozin, Meets Goals in Two Trials
Medscape Medical News, September 25, 2017
EASD Bariatric Surgery May Reduce Retinopathy Risk, Progression
Medscape Medical News, September 25, 2017
EASD Hyperkalemia Linked to Poor Outcomes in Diabetes Patients
Medscape Medical News, September 22, 2017
EASD J-DOIT3: 'Aim for Near-Normal Metabolic Parameters' in Diabetes
Medscape Medical News, September 21, 2017
EASD Artificial Sweeteners Alter Gut Response to Glucose
Medscape Medical News, September 20, 2017
EASD Aortic Aneurysm Risk Is Smaller in Type 2 Diabetes Patients
Medscape Medical News, September 20, 2017
EASD Evolocumab Doesn't Worsen Glycemia or Up Diabetes Risk: FOURIER
Medscape Medical News, September 19, 2017
EASD Simple Discussion of Emotions Reduces Diabetes Distress in Malaysia
Medscape Medical News, September 19, 2017

EASD CGM in Type 1 Diabetes in Pregnancy Cuts Adverse Neonate Outcomes
Medscape Medical News, September 18, 2017
EASD Minidose Glucagon for Exercise-Induced Hypoglycemia in T1D
Medscape Medical News, September 18, 2017
EASD Targeting Hypoglycemia and Glycemic Variability in T2D? More From DEVOTE
Medscape Medical News, September 15, 2017
EASD EXSCEL: 'Disappointment' Spurs Discussion on GLP-1 Agonists in Diabetes
Medscape Medical News, September 14, 2017
EASD Acarbose Offers No CVD Protection in ACE, but May Cut Diabetes Risk
Medscape Medical News, September 14, 2017
EASD DEPICT-1: Dapagliflozin Works in T1D With Little Ketoacidosis
Medscape Medical News, September 14, 2017
EASD Group CBT Does Not Maintain Weight Loss in Obese With Diabetes
Medscape Medical News, September 13, 2017
EASD 'Vote of Confidence for Sulfonylureas and Pioglitazone' in TOSCA IT
Medscape Medical News, September 13, 2017
EASD InTandem3: Sotagliflozin Has Benefits and Risks in Type 1 Diabetes
Medscape Medical News, September 13, 2017
EASD Fibrosis in Fat Tissue Predicts Poor Weight Loss After Surgery
Medscape Medical News, September 12, 2017
EASD CGM Benefits Type 1 Diabetes With Insulin Pumps or Shots
Medscape Medical News, September 12, 2017
EASD A Heavier Wife Predicts Diabetes Risk in Older Men
Medscape Medical News, September 11, 2017
EASD Ocean's Eleven: EASD in Lisbon Will Offer More Than 10 Trials
Medscape Medical News, September 5, 2017

Popular News from EASD 2016

Another Positive CV Outcomes Trial for Diabetes Drug: SUSTAIN-6 A second GLP-1 agonist, this time one not yet on the market, the once-weekly semaglutide, has shown positive results in a major cardiovascular-outcomes trial in type 2 diabetes patients at high CV risk.
Medscape Medical News, Sep 16, 2016
Half of All Type 1 Diabetes Develops After 30 Years of Age UK researchers find equal distribution of autoimmune-mediated diabetes below and above age 30 years, but after 30 this is "spotting a needle in a haystack," as cases are far exceeded by type 2 diabetes.
Medscape Medical News, Sep 20, 2016
Libre 'Flash' Glucose Monitoring System Cuts Hypoglycemia Experts weigh the relative pros and cons of the new Freestyle Libre "Flash" Glucose Monitoring System, which seems to be gaining in popularity among diabetes patients in Europe.
Medscape Medical News, Sep 20, 2016

Medscape Diabetes© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Expert Commentaries

Dapagliflozin: 'Helpful Strategy' for T1D?
John R. Petrie, MD, PhD
Renal and CV Disease Linked in Diabetes: 'Take Action'
Per-Henrik Groop, MD, DMSc
Diabetes Prevention 'Not Sexy,' but Essential
Christine Wiebe, MA
Pioglitazone, Sulfonylureas Safe and Effective in Type 2 Diabetes
Marja-Riitta Taskinen, MD, PhD
REMOVAL Update: More Benefits of Metformin in T1D
John R. Petrie, MD, PhD

Live Blog

News and Views from EASD 2017 Coverage of key advances and expert reactions as they happened at the meeting.

Previous Coverage